Development of antidepressant drugs for the 1990s: Progress or procrastination?

Heal, David J.; Buckett, W. R.

doi:10.1002/gps.930060616

Cited by 1 publication

(1 citation statement)

References 54 publications

(71 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The exact mechanism of action is unclear but probably involves actions at serotonin, noradrenaline, and/or dopamine synapses (169). Such drugs exhibit reduced toxicity, improved patient compliance, and lower toxicity in overdose than first-generation antidepressants.…”

Section: Atypical Antidepressantsmentioning

confidence: 99%

Psychopharmacological Agents

Martin

Godel

Hunkeler

et al. 2000

Kirk-Othmer Encyclopedia of Chemical Technology

View full text Add to dashboard Cite

Martin, James R.; Godel, T.; Hunkeler, W.; Jenck, F.; Moreau, J‐L.; Sleight, A. J.; and Widmer, U. (F. Hoffmann‐La Roche Ltd.). A number of important advances have occurred in the understanding and the treatment of disorders of the central nervous system including mood disorders, schizophrenia, anxiety disorders, insomnia, substance use disorders, and dementias. The plethora of novel drugs act by means of diverse neurobiological mechanisms and represent a great diversity of chemical structures. Along with improvements in the therapeutic index of anxiolytics, sedative–hypnotics, antidepressants, and antipsychotics, some progress has also been made in the search for drugs effective in the treatment of substance use disorders, as well as Alzheimer's disease and other dementias. Nonetheless, such improvements in symptomatic therapy have not been accompanied by the discovery of effective etiological and pathophysiological interventions. It is from here that the successful psychopharmacological agents of the future must come.

show abstract

Section: Atypical Antidepressantsmentioning

confidence: 99%